| Literature DB >> 30400655 |
Dorota Formanowicz1, Kaja Gutowska2, Piotr Formanowicz3,4.
Abstract
Interleukin 18 (IL-18) is one of the pro-inflammatory cytokines expressed by macrophages, suggesting that it plays important physiological and immunological functions, among the others: stimulation of natural killers (NKs) and T cells to interferon gamma (IFN- γ ) synthesis. IL-18 was originally identified as interferon gamma inducing factor and now it is recognized as multifunctional cytokine, which has a role in regulation of innate and adaptive immune responses. Therefore, in order to investigate IL-18 contribution to the immuno-inflammatory processes underlying atherosclerosis, a systems approach has been used in our studies. For this purpose, a model of the studied phenomenon, including selected pathways, based on the Petri-net theory, has been created and then analyzed. Two pathways of IL-18 synthesis have been distinguished: caspase 1-dependent pathway and caspase 1-independent pathway. The analysis based on t-invariants allowed for determining interesting dependencies between IL-18 and different types of macrophages: M1 are involved in positive regulation of IL-18, while M2 are involved in negative regulation of IL-18. Moreover, the obtained results showed that IL-18 is produced more often via caspase 1-independent pathway than caspase 1-dependent pathway. Furthermore, we found that this last pathway may be associated with caspase 8 action.Entities:
Keywords: Petri nets; atherosclerosis; interleukin 18; macrophages; modeling; t-invariants
Mesh:
Substances:
Year: 2018 PMID: 30400655 PMCID: PMC6274968 DOI: 10.3390/ijms19113476
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
List of places. The column “No.” includes the names of places and the column “Biological meaning” includes the names of biological or chemical components corresponding to places.
| No. | Biological Meaning | No. | Biological Meaning |
|---|---|---|---|
|
| active apoptotic peptidase activating factor 1 (APAF1) [ |
| foamy cells [ |
|
| apoptotic protease activating factor 1 (APAF1) and cytochrome c complex [ |
| high level of active caspase 8 active in type I cells [ |
|
| FAS-associated protein with death domain (FADD) recruited [ |
| high shear stress [ |
|
| large amounts of cell-surface FAS receptor (FAS) and FAS ligand (FASL) [ |
| inducible nitric oxide synthase (iNOS) [ |
|
| intercellular adhesion molecule 1 (ICAM1) |
| low level of active caspase 8 in type I cells |
|
| interferon gamma (IFN |
| modified, oxidized LDL [ |
|
| kinase complex (IKK complex made of two kinase IKK |
| nitric oxide (NO) [ |
|
| interleukin 18 (IL-18) [ |
| p50/p65 proteasome inhibitors induce inhibitory |
|
| interleukin 18 receptor (IL-18R) [ |
| p50/p65 dimer nuclear factor kappa-light-chain-enhancer of activated B cells (NF- |
|
| IRAK1P-TRAF6-TAB2-TAB1-TAK1 complex at plasma membrane, where: IRAK1P—interleukin 1 receptor-associated kinase 1 protein, TRAF6—TNF receptor associated factors 6 (TNF—tumor necrosis factor), TAB1 and TAB2—transforming growth factor (TGF TAK1—transforming growth factor (TGF |
| p50-p65 dimer nuclear factor kappa-light-chain-enhancer of activated B cells (NF- |
|
| interleukin 1 receptor-associated kinase 1 (IRAK1) degraded |
| peroxynitrite [ |
|
| Janus kinases and signal transducer and activator of transcription 1 (JAK/STAT1) pathway activated |
| pro-interleukin 18 (pro-IL18) [ |
|
| lipopolysaccharide binding protein (LBP) [ |
| pro-caspase 8 recruited |
|
| lipopolysaccharide (LPS) [ |
| radiation and/or toxins and/or hypoxia |
|
| lipopolysaccharide (LPS) and lipopolysaccharide binding protein (LBP) complex [ |
| truncated BH |
|
| monocyte chemotactic protein 1 (MCP1) |
| truncated BID in mitochondria |
|
| myeloid differentiation primary response gene 88 (MyD88) [ |
| signal transducer and activator of transcription 3 (STAT3) activated proteins [ |
|
| receptor-interacting protein 1 (RIP1) ubiquitinated |
| p50-p65 proteasome inhibitors induce inhibitory |
|
| receptors myeloid differentiation primary response gene 88 (MyD88) complex [ |
| interleukin 4 (IL-4) [ |
|
| TGF-beta activated kinase 1 (TAK1) activated |
| classically activated macrophages M1 [ |
|
| toll-like receptor 4 (TLR4) activated [ |
| a lot of classically activated macrophages M1 [ |
|
| TLR-MyD88-IRAK4-IRAK1P-TRAF6 complex, where: TLR—toll-like receptor, MyD88—myeloid differentiation primary response gene 88, IRAK4—interleukin-1 receptor-associated kinase 4, IRAK1P—interleukin 1 receptor-associated kinase 1 protein, TRAF6—TNF receptor associated factors 6 (TNF—tumor necrosis factor). |
| high level of interleukin 12 (IL-12) [ |
|
| TLR-MyD88-IRAK4-IRAK1P complex |
| no inflammation |
|
| TLR-Myd88-IRAK4 complex |
| active caspases 3, 6 and 7 [ |
|
| tumor necrosis factor receptor 1 (TNFR1) endocytosed |
| TNF-related weak inducer of apoptosis (TWEAK) changed concentration [ |
|
| tumor necrosis factor receptor 1 (TNFR1) stable with silencer of death domains (SODD) [ |
| high level of interleukin 10 (IL-10) [ |
|
| tumor necrosis factor alpha (TNF |
| subpopulation of activated T cells, T helper 2 (Th2) cells and cluster of differentiation (CD4) [ |
|
| TRAF2-TRADD-RIP1-TRAF5-TNFR1 complex, where: TRAF2 and TRAF5-TNF receptor associated factors 2 and 5, TNFR1—tumor necrosis factor receptor 1, TRADD—TNFR1-associated death domain protein, RIP1—receptor-interacting protein 1. |
| inactive caspase 1 [ |
|
| TNF receptor associated factors 2 (TRAF2) autoubiquitinated |
| lack of interleukin 18 (IL-18) [ |
|
| TNF-related apoptosis-inducing ligand (TRAIL) |
| cluster of differentiation (CD) 4 |
|
| TNF-related apoptosis-inducing ligand (TRIAL) death receptors DR5 and DR4 |
| natural killer (NK) cells [ |
|
| UBC13-UEV1A-TRAF6-TAK1P-TAB2P-TAB1 complex, where: UBC13 and UEV1A—ubiquitin-conjugating enzyme complex, TRAF6—TNF receptor associated factors 6, TAB2P—TGF TAB1—TGF |
| tissue macrophages |
|
| vascular cell adhesion molecule 1 (VCAM1) |
| interleukin 6 (IL-6) [ |
|
| active death-inducing signaling complex (DISC) type I cells [ |
| development of anti-inflammatory processes |
|
| active IL-18 and IL-18 receptors (IL-18R |
| interferon gamma (IFN |
|
| active TNF receptor associated factors 1 (TNFR1) signaling complex |
| interleukin 1 |
|
| apoptosome [ |
| interleukin 23 (IL-23) [ |
|
| cellular FLICE (FADD-like IL-1 |
| cytokines secreted by Th17 cells (IL-17, IL-21, and IL-22) [ |
|
| cardiovascular disease [ |
| human regulatory T cells |
|
| interleukin 1 |
| NADPH oxidase [ |
|
| contractility failure [ |
| interleukin 4 (IL-4) and interleukin 4 receptor (IL-4R) complex [ |
|
| cytochrome c [ |
| alternatively activated macrophages M2 with scavenger receptor A (SRA1) and cluster of differentiation 163 (CD163) [ |
List of transitions. The column “No.” includes the names of transitions and the column “Biological meaning” includes the names of biological functions of transition.
| No. | Biological Meaning | No. | Biological Meaning |
|---|---|---|---|
|
| pro-interleukin 18 (pro-IL-18) activation by caspase 1 enzymatic cleavage [ |
| inhibition of active caspase 8 in type I cells |
|
| IL-18 binding with IL-18R receptor [ |
| increase quantity of cFLIP [ |
|
| bacterial infection |
| apoptosis inhibition [ |
|
| caspase 8 dimerization autocleavage and activation type I cells (cells in which caspase-8 activation is sufficient to induce apoptosis) [ |
| intrinsic pathway of apoptosis [ |
|
| cleavage and activation of caspases 3, 6 and 7 |
| cytochrome c binding to apoptotic protease activating factor 1 (APAF1) [ |
|
| tumor necrosis factor receptor 1 (TNFR1) trimerization [ |
| triggering the formation of apoptosome [ |
|
| nitric oxide synthesis |
| caspase 1 inhibition [ |
|
| forming TRAF2-TRADD-RIP1-TRAF5-TNFR1 complex [ TRAF2 and TRAF5- tumor necrosis factor (TNF) receptor associated factors 2 and 5, TNFR1 - TNF receptor 1, TRADD - TNFR1-associated death domain protein, RIP1 - receptor-interacting protein 1. |
| trimerization of TNF-related apoptosis-inducing ligand (TRIAL) death receptors [ |
|
| pro-caspase 8 recruitment influenced by FADD [ |
| oncogenesis/inflammation [ |
|
| NADPH oxidase activity enhancement by TWEAK [ |
| silencer of death domains (SODD) binds to tumor necrosis factor receptor 1 (TNFR1) leading to its stabilization [ |
|
| lipids peroxydation |
| activation of signal transducer and activator of transcription 3 (STAT3) proteins phosphorylation by JAK via interleukin 6, interleukin 6 receptor and glycoprotein 130 complex (IL-6-IL-6R-gp130) on target cells (classical signaling pathway) [ |
|
| transformation into foamy cells |
| interleukin 4 receptor (type I IL-4R)) activation via binding with interleukin 4 (IL-4)and JAK1/JAK3 phosphorylation [ |
|
| binding lipopolysaccharide (LPS) and lipopolysaccharide binding protein (LBP) [ |
| signal transducer and activator of transcription 6 (STAT6) anti-inflammatory pathway [ |
|
| binding lipopolysaccharide (LPS) presentation to toll-like receptor 4 (TLR4) and cluster of differentiation 14 (CD14) and myeloid differentiation primary response 2 (Myd2) [ |
| IL-4 synthesis induced by M2 macrophages |
|
| p50-p65 translocation to the nucleus in macrophages M1, smooth muscle cell (SMC) and endothelial cell (EC) [ |
| release of interleukin 12 (IL-12) by classically activated macrophages M1 |
|
| toll-like receptor 4 and myeloid differentiation primary response 88 (TLR4-MyD88) connection via toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP) [ |
| inhibition of M1 macrophages specific gene expression [ |
|
| interleukin-1 receptor-associated kinase 4 (IRAK4) recruitment [ |
| apoptosis enhancement and anti-inflammatory response [ |
|
| connection with interleukin-1 receptor-associated kinase 1 (IRAK1) and its phosphorylation [ |
| interferon gamma (INF |
|
| TNF receptor associated factors 6 (TRAF6) recruitment and binding to interleukin 1 receptor- associated kinase 1 protein (IRAK1) [ |
| TNF-like weak inducer of apoptosis (TWEAK) sequestration |
|
| dissociation of interleukin 1 receptor-associated kinase 1 protein (IRAK1P) and TNF receptor associated factors 6 (TRAF6) [ |
| Interferon gamma (INF |
|
| phosphorylation of transforming growth factor (TGF |
| IL-18 negative regulation [ |
|
| TRAF6-TAK1P-TAB2P-TAB1 complex translocation to the cytosol [ TRAF6—tumor necrosis factor (TNF) receptor associated factors 6, TAK1P—transforming growth factor (TGF TAB2P—transforming growth factor (TGF TAB1—transforming growth factor (TGF |
| no action of IL-18 [ |
|
| TNF receptor-associated factor 6 (TRAF6) ubiquitination [ |
| adaptive immune response [ |
|
| phosphorylation of IKK- |
| innate immune response [ |
|
| connection of active IL-18, IL-18R |
| interferon gamma (IFN |
|
| tumor necrosis factor receptor 1 (TNFR1) clathrin-dependent internalization [ |
| transformation of tissue macrophages into M1 [ |
|
| receptor-interacting protein 1 (RIP1) ubiquitination |
| normal state [ |
|
| receptor-interacting protein 1 (RIP1) recruits transforming growth factor |
| release of interleukin 6 (IL-6) by classically activated macrophages M1 [ |
|
| connection through death domains (DDs) within FAS-associated protein with death domain (FADD) [ |
| processes leading to atherosclerotic plaque regression [ |
|
| recruitment of myeloid differentiation primary response gene 88 (MyD88) |
| T helper 17 (Th17) differentiation [ |
|
| pro-interleukin 18 (pro-IL-18) synthesis citeDNK+13 |
| release of interleukin 1 |
|
| atherosclerotic plaque progression |
| release of interleukin 23 (IL-23) by classically activated macrophages M1 [ |
|
| modulation by TNF |
| autoimmune inflammation, essential hypertension [ |
|
| attraction of monocytes |
| immune environment changes that stimulate human regulatory T cells (Treg) |
|
| neighboring endothelial cells stimulation |
| production of IL-10 by Treg |
|
| TNF receptor-associated factor 2 (TRAF2) ubiquitination |
| IL-10 enhances the M2 phenotype induced by IL-4 [ |
|
| recruitment of FAS-associated protein with death domain (FADD) [ |
| enhancement of M2 effector function |
|
| interferon gamma (IFN |
| NADPH oxidase activity source [ |
|
| oligomerization of the IFN |
| binding STAT1 with STAT binding element sequences of interferon regulatory factor 1 (IRF1) in IFN |
|
| cardiac contractile dysfunction [ |
| the FAS-FASL interaction [ |
|
| cardio-vascular disease symptoms [ |
| the proteasome pathway in activated SMC [ |
|
| modulation of T helper cells type 1 (Th1) differentiation during infections |
| smooth muscles cells (SMC) activation mechanisms [ |
|
| reactive oxygen species (ROS) generation in chronic kidney disease (CKD) especially during hemodialysis (HD) [ |
| IFN |
|
| cardiovascular events [ |
| regulation of migration and infiltration of monocytes/macrophages |
|
| BH |
| mediation of the adhesion of lymphocytes, monocytes, eosinophils, and basophils to vascular endothelium [ |
|
| kinase (IKK) complex activation [ |
| mediation of the adhesion between integrins on leukocytes and endothelial or epithelial cells [ |
|
| translocation of truncated BH |
| an inflammatory environment [ |
|
| release of cytochrome c from mitochondria to cytosol via mitochondrial perturbation [ |
| TRAIL production by different cells |
|
| activation of caspase 9 [ |
| IL-18 synthesis mediated by caspase 1-independent pathway |
List of non-trivial Maximal Common Transition (MCT) sets. The column “MCT set” contains the names of MCT sets. The column “Contained transitions” includes names of transitions contained in a given MCT set. The column “Biological interpretation” includes biological description (functions and mechanisms) of MCT sets.
| MCT Set | Subprocesses from | Contained Transitions | Biological Interpretation |
|---|---|---|---|
|
| d, e, h | IL-18R-mediated Myd88 signaling pathway. | |
|
| u | Intrinsic pathway of apoptosis. This pathway arises from signals that originate within the cell and is associated with BID cleavage via radiation, toxins or hypoxia. Truncated BID translocates to mitochondria and is involved in the release of active APAF1 and cytochrome c from mitochondria to the cytosol. Active APAF1 and cytochrome c create a complex, which leads to triggering the formation of apoptosome and activation of caspase 9. Active caspase (textcolorredinitiator caspase) initiates apoptosis by cleaving and thereby activating executioner caspases. | |
|
| b, e | Recognition of lipopolysaccharide pattern by TLR4 complexes. Activated TL4 is engaged on TLR and MyD88 connection via TIRAP. | |
|
| c, e | Activation of NF- | |
|
| y, r | IL-4–induced M2 polarization. Firstly, STAT3 activated by IL-6-IL6-R-gp130complex, influenced by high level of IL-10, induces binding IL-4 with type I IL-4R, which results in STAT6 pathway activation. | |
|
| k, n | High shear stress (mediated by ROS generation) and cardiac contractile dysfunction (affected by nitric oxide) lead to CVD. | |
|
| r | A lot of classically activated macrophages M1 release IL-1 and IL-23, which influence Th17 formation. Th17 cells are engaged in essential hypertension. | |
|
| g | Classically activated macrophages M1, under influence of an inflammatory microenvironment, induce IL-18 synthesis via cleavage of pro-IL-18 by caspase-1. | |
|
| p | SODD binds to TNFR1 and prevents self-aggregation and spontaneous downstream signaling at ligand absent (TNFR1 stabilization). SODD dissociates from TNFR1 upon receptor ligation. Binding of trimeric TNF | |
|
| p | Internalization of TNFR1 triggers pro-apoptotic signals (via the FAS-associated death domain adapter protein (FADD)). | |
|
| l | TRAF2-TRADD-RIP1-TRAF5-TNFR1 complex and cFLIP lead to TRAF2 ubiquitination and next to RIP1 ubiquitination, which recruits TAK1 (via TAB2). | |
|
| a, f | JAK-STAT pathway stimulated by IFN | |
|
| i | Nitric oxide leads to caspase 1 inhibition by S-nitrosylation of cysteine residues at the active sites. Negative regulation of IL-18 synthesis. | |
|
| y | Processes leading to atherosclerosis plaque regression have an influence on increasing anti-inflammatory pathways, which results in inhibition of M1 macrophage specific gene expression and alternatively in promotion of M2 macrophage specific gene expression. | |
|
| y | TWEAK–CD163-expressing M2 macrophages interaction. | |
|
| w | TRAIL or FasL bind their cognate receptors which induces receptor trimerization and formation of the death inducing signaling complex (DISC), type I cells comprising FADD and caspase-8. | |
|
| n | Peroxynitrite formation catalyzed by NADPH oxidase. | |
|
| t | Attracting of monocytes (influenced by TRAIL). | |
|
| x | Increased quantity of cFLIP can inhibit DISC formation by competing with caspase-8/10 for binding to FADD. | |
|
| t | TRAIL and its cognate receptors: death receptors (DR5 and DR4) trimerization. | |
|
| m | Transformation of tissue macrophages to M1 (a lot of classically activated macrophages M1). | |
|
| c | The heterodimer p50-p60 translocation to the nucleus in M1 macrophages, SMC and EC where it binds to specific |
List of t-clusters. The column “t-cluster” contains the names of t-clusters. The column “Biological meaning” includes biological interpretations of t-clusters.
| t-Cluster | Biological Meaning |
|---|---|
|
| TRAIL-induced apoptosis signaling pathways. Increased quantity of cFLIP leads to inhibition of caspase 8. |
|
| The mitochondria-involved intrinsic apoptotic pathway. The intrinsic pathway arises from signals that originate within the cell, as a consequence of cellular stress or DNA damage. High level of IL-10 has an influence on development of anti-inflammatory processes. Damage to mitochondria and subsequent apoptosome-mediated caspase 9 activation, which directly activate the effector caspase, caspase 3. |
|
| The mitochondria-involved intrinsic apoptotic pathway, similar to |
|
| TWEAK leads to the reaction catalyzed by NADPH oxidase, which results in peroxynitrite production. Macrophages M2 cause TWEAK sequestration in case of high level of IL-10. Peroxynitrite is engaged in lipids peroxidation and results in the production of modified oxidized LDL. This modified oxidized LDL together with IL-18 lead to neighboring endothelial cell stimulation and secretion of MCP1 (IL-18 is produced in caspase 1-independent pathway). |
|
| This cluster contains almost all processes included in the model, however it is missing: Caspase 1 inhibition caused by NO. TNFR1 endocytosis from TRAF2-TRADD-RIP1-TRAF5 complex, which leads to omission of FADD. Damage to mitochondria and subsequent apoptosome-mediated caspase 9 activation. |
|
| Attracting of monocytes caused by MCP1, VCAM1, ICAM1 (secreted via p50/p65 translocation to the nucleus in macrophages M1 and SMC and EC) and TRAIL (in oncogenesis) lead to a lot of classically activated macrophages M1. In oncogenesis TRAIL and death receptors trimerization leads to pro-caspase 8 recruitment by FADD. Connection through DDs within FADD and TNFR result in active DISC type I cells and increased quantity of cFLIP. cFLIP together with TRAF2-TRADD-RIP1-TRAF5-TNFR1 complex lead to TRAF2 ubiquitination and in consequence to RIP1 ubiquitination. RIP1 recruits TAK1 via TAB2, which is part of IKK complex engaged in phosphorylation of I |
|
| This cluster contains almost all processes included in the model; however, it is missing: Caspase 1 inhibition caused by NO. |
|
| This cluster contains almost all processes included in the model, however it is missing: IL-18 synthesis caused by caspase 1-dependent pathway. However, in this cluster IL-18 is produced in caspase 1-independent pathway. IL-12, IL-1, IL-23 release by classically activated macrophages M1. IFN gamma synthesis, what results in omission of JAK1, JAK2 and STAT1, STAT2 activation and also STAT1 protein via IFN gamma and IFNR. Omission of JAK- STAT1 pathway activation results in a lack of caspase 1 (a lack of modulation by TNF is also present). TNFR1 trimerization, which can create complex with TRAF2-TRADD-RIP1-TRAF5, which leads to the omission of FAD recruitment and TRAF2 ubiquitination. |
|
| This cluster contains almost all processes included in the model, however it is missing: IL-18 synthesis caused by caspase 1-dependent pathway. However, in this cluster IL-18 is produced in caspase 1-independent pathway. IL-12, IL-1, IL-23, IL-6 release by classically activated macrophages M1. High level of IL-10 release by alternatively activated macrophages M2. IFN gamma synthesis, which results in omission of JAK1, JAK2 and STAT1, STAT2 activation and also STAT1 protein via IFN gamma and IFNR. Omission of JAK- STAT1 pathway activation results in a lack of caspase 1 (a lack of modulation by TNF is also present). Caspase 8 inhibition. |
|
| Attracting of monocytes stimulated by TRAIL, MCP1 (by neighboring endothelial cells stimulation) and MCP1, VCAM1, ICAM1 (by p50/p65 translocation to the nucleus in macrophages M1 and SMC and EC) leads to high level of classically activated macrophages M1, which release IL-6, IL-12, IL-1, IL-23. Macrophages M1 are also engaged in the transformation of oxLDL into foamy cells via NO synthesis and lipid peroxidation, which results in progression of atherosclerotic plaque. IL-18 is produced in caspase 1-independent pathway and it can create complex with IL-18R (IL-18R is stimulated by bacterial infections). Active IL-18-IL-18R |
|
| Attracting of monocytes stimulated by TRAIL, MCP1, VCAM1, ICAM1 (by p50/p65 translocation to the nucleus in macrophages M1 and SMC and EC) lead to high level of classically activated macrophages M1, which release IL-6, IL-12, IL-1, IL-23. IL18 is produced in caspase 1-independent pathway and it can create complex with IL-18R (IL-18R is stimulated by bacterial infections). Active IL-18-IL-18R |
|
| Attract of monocytes stimulated by TRAIL, MCP1 (by neighboring endothelial cells stimulation) and MCP1, VCAM1, ICAM1 (by p50/p65 translocation to the nucleus in macrophages M1 and SMC and EC) leads to high level of classically activated macrophages M1, which release IL-6, IL-12, IL-1, IL-23. Macrophages M1 are also engaged in the transformation of oxLDL into foamy cells via NO synthesis and lipid peroxidation, which results in progression of atherosclerotic plaque. IL-18 is produced in caspase 1-independent pathway and it can create complex with IL-18R (IL-18R is stimulated by bacterial infections). Active IL-18-IL-18R |
|
| IFN gamma leads to interaction with IFNRs, which results in JAK1, JAK2 and STAT1, STAT2 activation. Activation of pathway of JAK-STAT1 leads to binding with SBE sequences of IRF-1. This process leads to NO synthesis induced by iNOS. NO is engaged in caspase 1 inhibition and in consequence leads to negative regulation of IL-18. NO synthesis leads also to peroxynitrite production, which together with high level of caspase 8 results in an activation of caspases 3, 6 and 7. High level of caspase 8 is caused by TRAIL and TRAIL death receptors trimerization (in oncogenesis). Active caspases 3, 6, 7 and also TWEAK lead to apoptosis enhancement anti-inflammation. TWEAK sequestration is caused by macrophages M2 in case of high level of IL-10. |
|
| IFN gamma leads to interaction with IFNRs, which results in JAK1, 2 and STAT1, STAT2 activation. Activation of pathway of JAK-STAT1 leads to binding with SBE sequences of IRF1. This process leads to NO synthesis induced by iNOS. NO is engaged in caspase 1 inhibition and in consequence leads to negative regulation of IL-18. NO synthesis leads also to peroxynitrite production, which is engaged in lipid peroxidation and results in production of modified oxLDL. This modified oxLDL together with IL-18 lead to neighboring endothelial cell stimulation and secretion of MCP1 (IL-18 is produced in caspase 1-independent pathway). |
|
| This cluster contains almost all processes included in the model, however it is missing: IL-18 synthesis caused by caspase 1-dependent pathway. However, in this cluster IL-18 is produced in caspase 1-independent pathway. Increased quantity of cFLIP, which results in omission of caspase 8 inhibition (and apoptosis inhibition) and omission of ubiquitination of TRAF2 and RIR1. Classically activated macrophages M1 via transformation of tissue macrophages. In this case, IL-1, IL-23 and L-12 are not released. IL-1 and IL-23 are engaged in Th17 cell formation, which leads to essential hypertension. IL-12 is engaged in IFN gamma synthesis. In this cluster, IFN gamma synthesis is caused by LPS (bacterial infection). |
List of t-clusters. The column “t-clusters” includes the names of t-clusters, the column “t-invariants” includes the names of t-invariants which are included in the particular t-cluster, the column “MCT set” includes the names of MCT set which are related to particular t-invariant and in the column “single transitions” two transitions have been distinguished: —activation of caspase 8 (marked with blue color) and —IL-18 synthesis mediated by caspase 1-independent pathway (marked with green color).
| t-Cluster | t-Invariants | MCT Set | Single Transitions |
|---|---|---|---|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
|
| ||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
|
| ||
|
| |||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
|
Figure 1The diagram presents a count of t-invariants corresponding to subprocesses in which IL-18 produced by different pathways is engaged.
Figure 2The diagram presents a count of t-invariants corresponding to subprocesses in which caspase 8 is engaged.
Figure 3The diagram presents a count of t-invariants corresponding to subprocesses in which different types of macrophages are engaged.
Comparison of t-clusters analysis and the more detailed analysis of particular t-invariants in terms of occurring of IL-18 and macrophages in subprocesses.
| Analysis of t-Clusters | The More Detailed Analysis of | |
|---|---|---|
| Subprocesses in Which IL-18 Is Engaged | ||
|
|
|
|
| Caspase 1-independent pathway | 10 (67%) | 66 (85%) |
| Caspase 1-dependent pathway | 0 (0%) | 3 (4%) |
| Caspase 1-independent pathway | 2 (13%) | 4 (5%) |
| lack of IL-18 | 3 (20%) | 5 (6%) |
|
| ||
|
|
|
|
| M1 | 1 (7%) | 16 (21%) |
| M2 | 4 (27%) | 5 (6%) |
| M1 and M2 | 8 (53%) | 54 (69%) |
| lack of macrophages | 2 (13%) | 3 (4%) |
Figure 4The diagram of the phenomena underlying the atherosclerotic lesions formation. The elements which are marked with the same colour and name correspond to the same particle (logic place). Element “51” corresponds to p50/p65 proteasome inhibitors induce inhibitory B (IB) phosphorylated complex within macrophages. Element “52” corresponds to p50/p65 dimer nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) early phase in activated endothelial cell (EC) in atherosclerosis. Element “53” corresponds to p50/p65 dimer nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B)) early phase in activated smooth muscle cells (SMC). Element “61” corresponds to p50/p65 proteasome inhibitors induce inhibitory B (IB) phosphorylated complex in activated SMC. Element “p50/p65” corresponds to p50/p60 translocation to the nucleus in macrophages M1 and SMC and endothelial cells (EC).
Figure 5The proposed model has been divided into parts corresponding to the biological phenomena: (a) Janus kinases and signal transducer and activator of transcription (JAK-STAT) pathway stimulated by interferon gamma (IFN); (b) innate immune responses; (c) p50/p65 translocation to the nucleus in macrophages M1, smooth muscle cell (SMC) and endothelial cell (EC); (d) gram-negative bacterial infections; (e) activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B)—the canonical pathway via IB phosphorylation by kinase complex (IKK) (MyD88-dependent signaling pathway); (f) activation of caspase 1 (by tumor necrosis factor (TNF) and also by binding with STAT binding element (SBE) sequences of interferon regulatory factor I (IRF1); (g) IL-18 synthesis (caspase 1-dependent pathway); (h) IL-18-IL-18R complex formation; (i) negative regulation of IL-18 (by inhibition of caspase 1) caused by nitric oxide (NO); (j) NO synthesis; (k) cardiovascular disease influenced by NO-dependent pathway; (l) TNF receptor-associated factor 2 (TRAF2) and receptor-interacting serine/threonine-protein (kinase 1 (RIP1) ubiquitination; (m) macrophages polarization; (n) lipid peroxidation (oxLDL); (o) IL-18 synthesis (caspase 1-independent pathway) and neighboring endothelial cells stimulation; (p) regulation of TNFR1 signaling; (r) the role of IL-1, IL-23, IL-6, high level of IL-10 and IL-12 (released by classically activated macrophages M1); (s) atherosclerosis progression; (t) attracting of monocytes (classically activated macrophages M1); (u) formation of apoptosome and activation of effector caspases 3, 6, 7; (w) high level of active caspase 8; (x) inhibition of caspase 8 and inhibition of apoptosis (by a high level of cFLIPs); (y) STAT6 upregulation promotes M2 macrophage polarization to suppress atherosclerosis.
Figure 6The scheme of work: creating models, methods of analysis, and obtaining results.
Figure 7The influence of different types of macrophages on IL-18. The results suggest that caspase 1-independent pathway may be associated with caspase 8 action.